Concepedia

Author

Jelena Urosevic

AstraZeneca (United States)ORCID

Also Known As

J. Urosevic, Jelena Urosevic

118

Publications

950

Citations

13

H-Index

25

Concepts

All Affiliations

AstraZeneca (United States)AstraZeneca (United Kingdom)AstraZeneca (Singapore)Vall d'Hebron Hospital UniversitariInstitució Catalana de Recerca i Estudis Avançats
JU

About

Jelena Urosevic is an author at AstraZeneca (United States) specializing in cell biology, medicine, and tumor biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

515

2

Cell Biology

4

4

515

3

Pharmacology

2

2

51

4

Engineering

1

1

36

5

Cancer Therapeutics

1

1

15

Jelena Urosevic

×

13

Publications

835

Citations

12

H-Index

YearCitations

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival

Matthias Drosten, Alma Dhawahir, Eleanor Y. M. Sum,

The EMBO Journal

2010

341

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer

Sylwia Gawrzak, Lorenzo Rinaldi, Sara Gregorio,

Nature Cell Biology

2018

123

Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome

Jelena Urosevic, Vincent Sauzeau, María Luisa Soto‐Montenegro,

Proceedings of the National Academy of Sciences

2011

70

Stratification and therapeutic potential of PML in metastatic breast cancer

Natalia Martín-Martín, Marco Piva, Jelena Urosevic,

Nature Communications

2016

58

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance

Mandy Lawson, Natalie Cureton, Susana R�os,

Cancer Research

2023

54

Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Nicolas Floc’h, Sangbin Lim, Sue Bickerton,

Molecular Cancer Therapeutics

2020

49

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cells

Steven W. Criscione, Matthew J. Martin, Derek B. Oien,

npj Precision Oncology

2022

36

Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer

Kavya Ramkumar, Azusa Tanimoto, Carminia M. Della Corte,

Clinical Cancer Research

2023

23

BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitors

Jordi Bertrán-Alamillo, Ana Giménez‐Capitán, Ruth Román,

Molecular Cancer

2023

21

Discovery and <i>In Vivo</i> Efficacy of AZ-PRMT5i-1, a Novel PRMT5 Inhibitor with High MTA Cooperativity

James M. Smith, Bernard Barlaam, David T. Beattie,

Journal of Medicinal Chemistry

2024

18

Page 1